GlassScriptPhysician profile
Charanjeev Kapoor
NPI 1891754685
$16,804.81
in general payments reported to CMS, 2019-2025
47 companies · $23.67 in 2025
The $23.67 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,473 · 2020: $6,664 · 2021: $3,159 · 2022: $179 · 2023: $126 · 2024: $180 · 2025: $23.67.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $308 · Education: $22.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $307.96 |
| Education | $22.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $5,296.32 | 2019-2022 | |
| Kite Pharma, INC. | $3,535.75 | 2019 | |
| Beigene USA, INC. | $1,350.00 | 2020 | |
| Epizyme, INC. | $1,250.00 | 2021 | |
| Innate Pharma, INC | $1,200.00 | 2020 | |
| Puma Biotechnology, INC. | $1,161.98 | 2019 | |
| Celgene Corporation | $680.93 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $320.87 | 2019-2024 | Xarelto, Rybrevant |
| Janssen Biotech, INC. | $245.82 | 2019-2024 | Erleada, Akeega |
| Pfizer INC. | $163.11 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $155.83 | 2019-2025 | |
| Astellas Pharma US INC | $128.68 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $124.39 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $116.79 | 2019 | |
| Merck Sharp & Dohme LLC | $108.97 | 2019-2021 |
Show all 46 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$54,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charanjeev Kapoor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.